Your browser doesn't support javascript.
loading
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Atisha-Fregoso, Yemil; Malkiel, Susan; Harris, Kristina M; Byron, Margie; Ding, Linna; Kanaparthi, Sai; Barry, William T; Gao, Wendy; Ryker, Kristin; Tosta, Patti; Askanase, Anca D; Boackle, Susan A; Chatham, W Winn; Kamen, Diane L; Karp, David R; Kirou, Kyriakos A; Sam Lim, S; Marder, Bradley; McMahon, Maureen; Parikh, Samir V; Pendergraft, William F; Podoll, Amber S; Saxena, Amit; Wofsy, David; Diamond, Betty; Smilek, Dawn E; Aranow, Cynthia; Dall'Era, Maria.
Afiliación
  • Atisha-Fregoso Y; Feinstein Institute for Medical Research, Manhasset, New York.
  • Malkiel S; Feinstein Institute for Medical Research, Manhasset, New York.
  • Harris KM; Immune Tolerance Network, Bethesda, Maryland.
  • Byron M; Rho, Durham, North Carolina.
  • Ding L; National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
  • Kanaparthi S; Immune Tolerance Network, Bethesda, Maryland.
  • Barry WT; Rho, Durham, North Carolina.
  • Gao W; National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
  • Ryker K; Immune Tolerance Network, Bethesda, Maryland.
  • Tosta P; Immune Tolerance Network, Bethesda, Maryland.
  • Askanase AD; Columbia University Medical Center, New York, New York.
  • Boackle SA; University of Colorado, Denver.
  • Chatham WW; University of Alabama at Birmingham, San Francisco.
  • Kamen DL; Medical University of South Carolina, Charleston.
  • Karp DR; UT Southwestern Medical Center, Dallas, Texas.
  • Kirou KA; Hospital for Special Surgery, New York, New York.
  • Sam Lim S; Emory University, Atlanta, Georgia.
  • Marder B; Medical Center of Aurora, Aurora, Colorado.
  • McMahon M; University of California, Los Angeles.
  • Parikh SV; Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Pendergraft WF; University of North Carolina Kidney Center, Chapel Hill.
  • Podoll AS; University of Colorado, Denver.
  • Saxena A; NYU School of Medicine, New York, New York.
  • Wofsy D; University of California, San Francisco.
  • Diamond B; Feinstein Institute for Medical Research, Manhasset, New York.
  • Smilek DE; Immune Tolerance Network, Bethesda, Maryland.
  • Aranow C; Feinstein Institute for Medical Research, Manhasset, New York.
  • Dall'Era M; University of California, San Francisco.
Arthritis Rheumatol ; 73(1): 121-131, 2021 01.
Article en En | MEDLINE | ID: mdl-32755035
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nefritis Lúpica / Ciclofosfamida / Anticuerpos Monoclonales Humanizados / Rituximab / Inmunosupresores Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: Arthritis Rheumatol Año: 2021 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nefritis Lúpica / Ciclofosfamida / Anticuerpos Monoclonales Humanizados / Rituximab / Inmunosupresores Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: Arthritis Rheumatol Año: 2021 Tipo del documento: Article